Emerging Veterinary Practice Consolidators 2026: What GP Owners Need to Know

Key takeaways

• A new class of consolidator is building the next generation of veterinary chains — Bond Vet, Modern Animal, GoodVets, Petfolk, Small Door, and Heart + Paw have collectively raised hundreds of millions in institutional capital and are opening new clinics at speed in 2026.
• Most of these groups grow de novo, not through acquisitions. They build new locations from scratch rather than buying existing practices — which means they are not in the market to purchase your established practice, and understanding that distinction matters before you respond to any outreach.
• The established institutional buyer pool is still where the highest outcomes come from for a $2M+ GP owner. NVA, VetCor, PetVet, AmeriVet, Mission Pet Health, and others acquire established practices and compete against each other in structured processes — that competition is what moves the number.
• Emerging consolidators are worth understanding as market context even if they are not your buyer. They signal capital confidence in the sector, and a few — particularly Heart + Paw’s co-ownership program — are increasingly relevant to associate veterinarians considering practice ownership.
• The 2026 market still rewards preparation and competition above all else. Capstone Partners’ April 2026 Pet Sector M&A Update counted 18 announced or completed transactions in YTD 2026, more than double the same period in the prior year — active buyers remain, and a properly run process still generates real leverage.

I got a call last spring from a vet who had received an email from a company I hadn’t run a transaction with. She’d Googled it, seen sleek marketing and a press mention about a nine-figure funding round, and was wondering whether she should take the meeting.

It was a de novo-focused group — meaning they build new clinics from scratch rather than acquiring existing practices. They weren’t calling to buy her practice.

They were calling to explore whether she’d be interested in opening a new location with them under a co-ownership arrangement.

She almost missed a real sale process by walking down the wrong hall.

That’s the conversation I keep having with practice owners in 2026. The veterinary sector has attracted a second wave of well-capitalized groups — not the NVAs and VetCors of the world, but a newer set of platforms backed by growth equity and venture capital. Knowing who they are, what they actually do, and whether they are relevant to you as a seller is the kind of context that keeps your focus where it belongs.

Emerging veterinary practice consolidators in 2026 are groups that have entered the market since roughly 2019, typically grow through de novo clinic builds rather than acquisitions, and are backed by growth equity, venture capital, or smaller PE firms rather than the large buyout sponsors that back the established buyer pool. The most visible names — Bond Vet, Modern Animal, GoodVets, Petfolk, Small Door, and Heart + Paw — have collectively raised well over $500 million in institutional capital and are now operating at regional or national scale in certain markets.

Why 2026 is the year to understand this landscape

PE-backed and institutional veterinary groups of all types now own approximately 22% of all veterinary practices in the US, up from 16% just three years ago, per the 2026 AVMA Economic Report. That number is still rising. Capstone Partners‘ April 2026 Pet Sector M&A Update tallied 18 announced or completed transactions in the pet sector through year-to-date 2026, more than double the 8 transactions in the same period of the prior year, driven by a stronger pipeline of assets coming to market as PE-backed platforms approach fund lifecycle exits.

The sector has two distinct buyer categories now. The established institutional buyers — PE-backed groups with hundreds of locations and multi-billion-dollar backers — are the ones actively acquiring existing independent practices and bidding competitively for them.

The emerging category, which this article covers, is mostly building new locations alongside those acquisitions. Understanding the distinction is the first act of preparation for any owner considering a sale.

Bond Vet: urgent care meets primary care, Northeast-first

Bond Vet is one of the clearest examples of what this second wave looks like at scale. Founded in 2019 and backed by a $170 million growth investment from Warburg Pincus (announced 2021), Bond Vet now operates more than 57 locations across 8 states and Washington, DC, concentrated in New York, New Jersey, Massachusetts, Pennsylvania, and the mid-Atlantic corridor.

Their model is a hybrid of urgent care and general practice. Same-day and walk-in appointments, extended weekend hours, an in-house pharmacy, surgical and diagnostic equipment, telehealth, and a 24/7 pet parent helpline.

Bond Vet has also partnered with AI documentation platform VetRec to automate clinical documentation across its 55+ locations, per a 2025 announcement — a signal of where tech-enabled platform operators are investing.

What Bond Vet is and is not, for a GP owner: Bond Vet has expanded primarily through de novo location builds rather than acquisitions of existing practices. A practice owner in the Northeast receiving outreach from Bond Vet or seeing them compete for talent in their market should understand Bond Vet as a de novo competitor, not a buyer of their practice.

The institutional buyers who do actively acquire existing GP practices are the groups to engage through a structured competitive process. You can learn more about the broader landscape in our veterinary practice consolidators overview.

GoodVets: de novo general practice at high speed

GoodVets is the most aggressive de novo builder in the general-practice segment right now. Backed by General Atlantic (a growth equity investment announced September 2023, adding to prior backing from SkyKnight Capital and Dixon Midland), GoodVets had grown from 22 locations in 11 cities at the time of the General Atlantic announcement to 75 active or under-construction locations across 22 cities by late 2024, per their published location data.

Their geographic footprint is broad: Chicago, Atlanta, Miami, Tampa, Nashville, Charlotte, Denver, with New York, Los Angeles, and Dallas in active expansion. GoodVets partners with entrepreneur-minded veterinarians who act as local hospital owners while drawing on GoodVets’ centralized resources — training, marketing, technology, compensation structures.

The de novo model (building new from scratch rather than acquiring existing practices) is the defining feature here. GoodVets is not acquiring independent established practices.

They are building adjacent competition to them in many of the same metro markets. A general-practice owner in a GoodVets market should know they’re building, not buying.

For owners thinking about their valuation in those markets, the arrival of GoodVets as a de novo competitor is worth noting in a pre-sale operational planning conversation. It affects recruitment dynamics and new-client flow in the medium term.

The actual decision on buyers and timing, though, runs through the institutional buyer pool — the groups that actually bid on established practices. See our guide on how to choose who to sell your veterinary practice to for that framework.

Modern Animal: VC-backed technology-first veterinary

Modern Animal sits at the intersection of veterinary care and consumer tech. Backed by a roster of venture investors including Addition, Upfront Ventures, True Ventures, and Founders Fund, Modern Animal closed a $46 million Series D in September 2025, per a Fortune exclusive.

Total equity raised exceeds $229 million.

The company operates 27 clinics across California, Texas, and Colorado, serving primarily millennial pet owners in urban and Sun Belt markets. In 2024 they reached a $100 million revenue run rate with 85% year-over-year revenue growth, per their own press release.

Modern Animal’s model offers 2 service tiers: an All-Access membership at $199/year (unlimited exams) and a pay-as-you-go option at $80/exam. Membership subscriptions account for roughly 12% of revenue; the balance comes from in-clinic services, diagnostics, procedures, and pharmacy.

Their 2025 capital raise supports an integrated ecommerce pharmacy platform and expanded urgent care hours.

The profile here is unmistakably VC — a loss-tolerating growth story aimed at eventual scale or exit, not an established operator looking to acquire mature GP practices. Modern Animal’s growth has been de novo-first in California, then expanding to Texas and Colorado.

They are a meaningful competitor in their markets for millennial-urban pet owner attention, but they are not buyers of established GP practices in the traditional sense.

Petfolk: connected care in the Southeast and Sunbelt

Petfolk takes a different approach than the pure tech plays. Founded by Dr.

Audrey Wystrach (a co-founder of Austin-based Zippivet, one of the earlier de novo multi-practice groups), Petfolk’s model combines modern de novo clinic builds with 24/7 app-based virtual care — what they call a “connected care” model. Think in-clinic for the exam, then app-based follow-through for questions, prescription refills, and telehealth.

Petfolk received a $36 million Series C investment led by Deerfield Management (announced October 2024), following a $40 million Series B in 2023. The Series C supported expansion from 19 clinics across 7 Southeastern and Sunbelt markets (Charlotte, Raleigh, Atlanta, Orlando, Dallas, Houston, San Antonio) to approximately 40 clinics across 10+ markets by end of 2025, with Miami and Phoenix added per their published expansion roadmap.

Petfolk has also launched the Petfolk Partner Program, which gives associate veterinarians a path from employed associate to partner, with shared clinic economics and equity ownership in Petfolk — no buy-in required. This is distinct from their growth strategy: the partner program retains and incentivizes DVMs; it does not involve acquiring existing independent practices from their owners.

For an independent GP owner in a Petfolk market: you are competing for talent with a group that offers equity upside and a modern practice environment. That’s the operational context.

Petfolk is not a buyer of your established practice; they are building alongside it. The sale path for your practice runs through the established institutional acquirers who have both the track record and the financial model to bid competitively for an existing practice’s goodwill and client base.

Our earnout and rollover equity guide explains the deal structure you’ll encounter in those conversations.

Small Door: membership-first, East Coast concentrated

Small Door Veterinary is the clearest membership-model operator in the group. Headquartered in New York, Small Door raised $55 million in Series C capital in 2025 — a $35 million equity financing led by Valspring Capital plus a $20 million debt facility from Bridge Bank — bringing total equity raised to $98.5 million, per Business Wire.

Their membership is $149/year per pet and covers preventive care plus access to 24/7 telemedicine. Members receive same-day appointments and a “stress-free” clinic environment explicitly designed to reduce patient anxiety.

Small Door operates in New York, Boston, and Washington, DC — three high-density, high-income urban markets where demand for concierge-adjacent veterinary care is strong.

The membership model generates predictable recurring revenue that funds clinical talent. Their 2025 raise supports scaling the membership model beyond their East Coast base.

Like Modern Animal, Small Door’s identity is technology-enabled and membership-driven; unlike some of the other groups here, their geography is narrow and urban, not national.

Again: Small Door is not acquiring established suburban GP practices. Their market is urban and their model is de novo.

Heart + Paw: co-ownership and the multi-service model

Heart + Paw is worth spending more time on, because their model is the most distinctive of the group and the most relevant to DVMs thinking about practice ownership rather than practice sale.

Backed by Whistler Capital Partners (a healthcare-focused PE firm; investment announced January 2024), Heart + Paw operates 28 locations across 10 states and offers veterinary care, grooming, daycare, and boarding in an integrated pet care center format. They were founded in 2018 and have been growing through a veterinarian co-ownership / joint venture de novo model: a vet helps design, build, and co-own a Heart + Paw center, with Heart + Paw providing capital, brand, operational support, and mentorship.

In January 2025, Heart + Paw announced Dr. Mary Peacock as Chief Veterinary Officer, signaling a deepened clinical leadership commitment alongside the business expansion.

Their co-ownership model is available to entrepreneurial DVMs on the East Coast and is expanding geographically.

The distinction that matters: Heart + Paw’s co-ownership offer is to practicing DVMs who want to build and own a new location — not to established practice owners who want to sell an existing one. If you own a $3 million GP practice and are considering a sale, Heart + Paw’s model is not your path.

The competitive offer for your existing practice, your goodwill, your client base, and your trained team comes from the established institutional buyer pool. Heart + Paw acquires the Homestead Veterinary Center in the Poconos, per a 2024 press release — so some traditional acquisitions do occur — but the platform strategy is de novo-first.

What GP owners with $2M+ in revenue should actually take from all this

The pattern I see in every one of these emerging groups is consistent: growth equity or venture capital in, de novo clinics out. That is a fundamentally different capital model than the PE-backed roll-ups that dominate the established buyer pool.

PE-backed roll-ups (NVA, VetCor, PetVet, AmeriVet, Mission Pet Health, and the rest) are building platforms to sell. They acquire existing practices because they need goodwill, client bases, and trained teams quickly — and they compete against each other for the best practices, which is exactly what creates leverage for a seller running a structured process.

Emerging de novo groups are building platforms to hold (at least for now) or to reach scale for a future IPO or sponsor-to-sponsor transaction. They need square footage and DVMs, not your existing client file.

The practical implication: for a practice owner with $2M+ in revenue thinking about a sale in the next 12 to 36 months, the emerging groups covered in this article are market context, not buyers. Understanding them helps you see the full competitive landscape, make sense of talent recruiting dynamics in your market, and recognize what kind of call is actually worth your time. An approach from a de novo group is interesting.

A structured process with the institutional buyer pool is where the real number gets made.

Axios reported in February 2026 that PE-backed veterinary platforms are feeling pressure to exit as fund lifecycles mature — which means more of those platforms are actively acquiring well-run practices to build scale before their own sponsor exit. That pressure keeps the acquisition market active, and it keeps the buyer pool competitive for sellers who position their practices correctly.

How emerging consolidator dynamics affect your valuation conversation

Here’s the angle most owners miss. The presence of well-capitalized de novo groups in your market isn’t irrelevant to your valuation — it just affects it indirectly.

On talent: de novo groups hiring DVMs at competitive rates in your market can compress your own staffing. A practice that has replaced an owner-doctor with a stable associate base before the sale process converts personal goodwill into enterprise goodwill — the transferable kind.

If a de novo competitor is recruiting aggressively in your metro, getting ahead of associate retention is both a business priority and a pre-sale one.

On new-client flow: in markets where GoodVets, Bond Vet, or Petfolk have opened new locations, new-client acquisition for established independents has tightened in some demographics. A practice’s existing loyal client base and retention metrics become a stronger selling point to buyers in those markets — because the argument is about depth of relationship, not new-client growth.

On the multiple: none of the emerging groups listed here have disclosed acquisition pricing or publicly entered the market to acquire $2M+ GP practices at scale. What moves your multiple is whether established institutional buyers compete against each other for your practice.

That’s what we build at Transitions Elite — the Elite Selling System, where we hand-select and vet every buyer who gets to bid on a practice, the way a doorman with a velvet rope lets in only the right people, then run a private competitive bidding window inside that qualified group.

The gap between a direct offer from a single buyer and what the same practice clears through a properly run competitive process is consistently meaningful. We see it in our deal flow year after year.

Understanding the buyer landscape — who the real acquirers are and who the de novo builders are — is the first step toward making sure you’re running your process with the right group at the table.

What to do next

If you own a general-practice veterinary clinic with $2M or more in annual revenue and you’re thinking about a sale in the next 1 to 3 years, the right starting point is understanding what your practice would actually clear in a competitive process today — not what any single buyer has informally told you.

That number usually looks different from what people expect. We build it from actual deal data across our closed transactions, and we do it as part of a free initial engagement with no pressure and no commitment.

Get a Free Practice Value Estimate →

When you reach out, we’ll review your financials, benchmark your practice against current deal activity in our pipeline, and give you a realistic read on where your practice would price in today’s market. That conversation doesn’t cost anything, and it doesn’t obligate you to anything.

It just tells you where you stand.

We are a sell-side-only advisory firm. We don’t represent buyers.

We represent owners — and we only get paid when a deal closes at a number you’ve decided to accept.

---

Frequently asked questions

Who are the emerging veterinary practice consolidators in 2026?

The most active emerging veterinary consolidators in 2026 include Bond Vet (Warburg Pincus, 57+ locations, Northeast-focused urgent and primary care), Modern Animal (VC-backed, 27 clinics, California/Texas/Colorado, technology-first model), GoodVets (General Atlantic, 75+ locations across 22 cities, de novo general practice), Petfolk (Deerfield Management Series C, 19+ clinics, Southeast and Sunbelt, connected care model), Small Door (Series C 2025, membership-first model, New York/Boston/DC), and Heart + Paw (Whistler Capital Partners, 28 locations, co-ownership de novo model).

How do emerging veterinary consolidators differ from established ones like NVA or VCA?

Established consolidators like NVA and VCA grow primarily through acquiring existing practices and their goodwill, client base, and trained teams. Most emerging consolidators in 2026 favor the de novo strategy — building new locations from scratch — which means they are not in the market to buy your existing practice.

A GP owner with $2M+ in revenue considering a sale is still best served by the established institutional buyer pool, where competitive bidding among multiple qualified buyers drives the highest outcomes.

Do Bond Vet, Modern Animal, or GoodVets buy existing veterinary practices?

These groups primarily grow through de novo clinic builds rather than by acquiring existing independent practices. Bond Vet, GoodVets, Petfolk, and Modern Animal have each stated a de novo-first strategy in their funding announcements.

Heart + Paw operates a co-ownership model where veterinarians co-invest in new locations. None of these groups are currently active buyers of established independent GP practices in the way that NVA, VetCor, PetVet, AmeriVet, or Mission Pet Health are.

What is a de novo veterinary consolidator strategy?

A de novo strategy means the consolidator builds new clinic locations from scratch — signing leases, designing and outfitting spaces, hiring clinical staff — rather than acquiring an existing practice’s goodwill, client base, and team. De novo growth avoids the premium paid for established practices and gives the platform full control over brand standards and technology from day one, but it requires more capital and time to reach profitability per location than an acquisition-driven approach.

What is Heart + Paw’s co-ownership model for veterinarians?

Heart + Paw, backed by Whistler Capital Partners, offers veterinarians a path to co-own a new de novo location. The veterinarian helps design, build, and operate the center while Heart + Paw provides capital, operational infrastructure, marketing, and mentorship.

This is a joint venture structure, not a practice acquisition. The vet co-invests rather than selling an existing practice, and Heart + Paw handles the platform-level resources needed to run a multi-service pet care center.

What is Small Door’s membership veterinary model?

Small Door Veterinary operates a membership-first model at $149 per year, which covers preventive care and grants members access to 24/7 telemedicine. In 2025 they raised $55 million in Series C capital to scale from their East Coast base.

Members receive same-day appointments, a stress-free clinic environment, and transparent pricing. The model is built around preventive engagement and recurring revenue rather than high-volume transactional visits.

Should I consider an emerging consolidator offer or wait for an established buyer?

For a GP owner with $2M+ in revenue, the established institutional buyer pool — NVA, VetCor, PetVet, AmeriVet, Mission Pet Health, and others — is where meaningful competitive offers come from. Emerging, de novo-focused consolidators are generally not active acquirers of established practices.

Running a structured competitive process with multiple qualified institutional bidders is consistently how sellers achieve the highest after-tax proceeds — because competition, not any single buyer’s direct offer, moves the number.

How much do veterinary practices sell for in 2026?

Across our deal flow, multi-doctor GP practices with $2M+ in revenue that run a structured competitive process consistently clear well into the double-digit EBITDA multiple range. In 2025 specifically, the average across our closed transactions climbed past eleven times EBITDA, and the median deal cleared closer to thirteen.

A single direct offer from one buyer — without competition — typically delivers a meaningfully lower outcome than a properly run competitive process.

---

Sources

Industry M&A research and valuation data

1. Capstone Partners. “Pet Sector M&A Update — April 2026.” capstonepartners.com
2. GlobalPETS. “Deal or no deal? Pet industry M&A in 2026.” globalpetindustry.com
3. Axios. “Private equity firms find COVID-fueled veterinarian deals hard to exit.” February 2026. axios.com

Veterinary practice profession and ownership data

4. American Veterinary Medical Association (AVMA). 2026 Economic Report. Referenced in Petconomist analysis. avma.org
5. AAHA. “Corporate consolidation and the rise of private equity.” aaha.org
6. Frontiers in Veterinary Science. “Making the case for a resurgent U.S. independent veterinary practice segment: a SWOT analysis.” 2025. frontiersin.org

Public company disclosures and PE/VC filings

7. Warburg Pincus / Bond Vet. “Bond Vet Announces Growth Investment from Warburg Pincus.” PR Newswire, 2021. prnewswire.com
8. General Atlantic / GoodVets. “GoodVets Announces Strategic Growth Investment from General Atlantic.” Business Wire, September 2023. businesswire.com
9. Deerfield Management / Petfolk. “Petfolk Receives Series C Investment Led by Deerfield Management.” PR Newswire, October 2024. prnewswire.com
10. Small Door Veterinary. “Small Door Veterinary Raises $55 Million to Scale Proven Membership-Based Model.” Business Wire, 2025. businesswire.com
11. Whistler Capital Partners / Heart + Paw. “Heart + Paw Receives Significant Strategic Growth Investment from Whistler Capital Partners.” Business Wire, January 2024. businesswire.com
12. Modern Animal. “Modern Animal Announces $100M Run Rate, Funding, and Board Expansion.” PR Newswire, September 2025. prnewswire.com